ATE124269T1 - Verfahren zur herstellung eines mit metall- radionuklid-markierten proteins. - Google Patents

Verfahren zur herstellung eines mit metall- radionuklid-markierten proteins.

Info

Publication number
ATE124269T1
ATE124269T1 AT89904426T AT89904426T ATE124269T1 AT E124269 T1 ATE124269 T1 AT E124269T1 AT 89904426 T AT89904426 T AT 89904426T AT 89904426 T AT89904426 T AT 89904426T AT E124269 T1 ATE124269 T1 AT E124269T1
Authority
AT
Austria
Prior art keywords
protein
proteinaceous material
radionuclide
reacting
coupling
Prior art date
Application number
AT89904426T
Other languages
English (en)
Inventor
Wilhelmus Theodorus Goedemans
Karel Jan Panek
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of ATE124269T1 publication Critical patent/ATE124269T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/36—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT89904426T 1988-02-09 1989-02-08 Verfahren zur herstellung eines mit metall- radionuklid-markierten proteins. ATE124269T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL8800302 1988-02-09
NL8801728 1988-07-08
NL8802408 1988-09-30

Publications (1)

Publication Number Publication Date
ATE124269T1 true ATE124269T1 (de) 1995-07-15

Family

ID=27352196

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89904426T ATE124269T1 (de) 1988-02-09 1989-02-08 Verfahren zur herstellung eines mit metall- radionuklid-markierten proteins.

Country Status (7)

Country Link
EP (1) EP0401302B1 (de)
AT (1) ATE124269T1 (de)
AU (2) AU635204B2 (de)
DE (1) DE68923274T2 (de)
FI (1) FI903917A7 (de)
IL (1) IL89222A (de)
WO (1) WO1989007456A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006774A1 (en) * 1988-12-22 1990-06-28 Xoma Corporation Hindered linking agents and methods
FR2650749B1 (fr) * 1989-08-08 1994-09-02 Univ Rouen Methode de diagnostic et/ou de traitement, notamment du cancer
CA2065362A1 (en) * 1989-08-24 1991-02-25 Fook-Thean Lee Radio-labelled antibodies for imaging
JPH05504763A (ja) * 1989-11-30 1993-07-22 マリンクロッド・メディカル・インコーポレイテッド 金属放射性核種でラベル付けされたタンパク質の調製方法
EP0485664A1 (de) * 1990-11-13 1992-05-20 Mallinckrodt Diagnostica (Holland) B.V. Verfahren zur Herstellung von einem diagnostischen Mittel zur Feststellung von Entzündungen
FI920459A7 (fi) * 1991-02-05 1992-08-06 Cis Bio Int Menetelmä teknetium-99m:llä leimatun elinspesifisen aineen valmistamiseksi
US7238340B1 (en) 1991-11-27 2007-07-03 Cis Bio International Monoamine, diamide, thiol-containing metal chelating agents
US5443815A (en) * 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5997844A (en) * 1991-02-08 1999-12-07 Diatide, Inc. Technetium-99m labeled peptides for imaging
US5849261A (en) * 1991-02-08 1998-12-15 Diatide, Inc. Radiolabeled vasoactive intestinal peptides for diagnosis and therapy
US5965107A (en) * 1992-03-13 1999-10-12 Diatide, Inc. Technetium-99m labeled peptides for imaging
WO1992018536A2 (en) * 1991-04-22 1992-10-29 Mallinckrodt Medical, Inc. Method for detecting an localizing tissues having neurokinine 1 receptors
US5783170A (en) * 1991-11-27 1998-07-21 Diatide, Inc. Peptide-metal chelate conjugates
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5508020A (en) 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
US5879657A (en) * 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
CA2141739A1 (en) * 1993-05-03 1994-11-10 Alfons M. Verbruggen Method for preparing a metal-radionuclide-labelled protein
ES2114209T3 (es) * 1993-07-19 1998-05-16 Resolution Pharm Inc Queladores de radionuclidos de tipo hidrazino que tienen una configuracion n3s.
US5858327A (en) * 1993-09-03 1999-01-12 Resolutions Pharmaceuticals, Inc. Hydrazino-type N2 S2 radionuclide chelating compounds
US5574140A (en) * 1993-09-03 1996-11-12 Resolution Pharmaceutical Inc. Hydrazino-type N2 S2 chelators
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
US6043256A (en) * 1996-09-16 2000-03-28 Grassetti; Davide R. Antimutagenic agents
KR100367125B1 (ko) * 1996-12-02 2003-08-27 그라코 인크. 패턴제어식분배장치
EP2380597A1 (de) 2010-04-20 2011-10-26 Technische Universität München Cyclopeptid-Derivate und deren Verwendungen
EP2380596A1 (de) 2010-04-20 2011-10-26 Technische Universität München Cyclopentapeptid-Derivate und deren Verwendungen
PL3152226T3 (pl) 2014-06-06 2019-10-31 Univ Muenchen Tech Modyfikowane cyklopentapeptydy i ich zastosowania

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3223585A (en) * 1965-02-23 1965-12-14 American Cyanamid Co Pesticidal monosulfur heterocyclic compositions
JPS5835520B2 (ja) * 1976-06-01 1983-08-03 株式会社第一ラジオアイソト−プ研究所 ６−カルボキシメチルチオコルチゾ−ルおよびその誘導体
US4479930A (en) * 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4652519A (en) * 1983-02-03 1987-03-24 Yeda Research And Development Company Limited Bifunctional chelating agents and process for their production
ATE66469T1 (de) * 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling

Also Published As

Publication number Publication date
EP0401302B1 (de) 1995-06-28
FI903917A0 (fi) 1990-08-08
IL89222A (en) 1995-03-30
EP0401302A4 (de) 1994-03-30
WO1989007456A1 (en) 1989-08-24
DE68923274D1 (de) 1995-08-03
AU3368689A (en) 1989-09-06
AU635204B2 (en) 1993-03-18
FI903917A7 (fi) 1990-08-08
DE68923274T2 (de) 1995-11-09
IL89222A0 (en) 1989-09-10
AU3105693A (en) 1993-02-25
AU658959B2 (en) 1995-05-04
EP0401302A1 (de) 1990-12-12

Similar Documents

Publication Publication Date Title
ATE124269T1 (de) Verfahren zur herstellung eines mit metall- radionuklid-markierten proteins.
US5053503A (en) Chelating agents
US4837003A (en) Radiolabeled antibody fragments
EP0178125B1 (de) Markierte Antikörperfragmente.
CA1234800A (en) Processes for the preparation of new conjugates of vinblastine or of vinblastine derivatives and the products of such processes
CA1288197C (en) Metal ion labeling of carrier molecules
JPS61191675A (ja) 巨大分子物質
US5218128A (en) Bifunctional coupling agents and radionuclide labeled compositions prepared therefrom
HUT56288A (en) Crosslinked antibodies and process for their production
GR3034883T3 (en) Molecule labelling using 2-hydraninopyridine derivatives.
EP0895991A3 (de) Halogenierungsmittel
Itano et al. 4-Thialaminine, a strongly basic chemical modification of cysteine
KR840003631A (ko) 아졸릴펜옥시- 테트라하이드로푸란-2-일리덴- 메탄의 제조방법
YU72000A (sh) Kompleks platine, njegovo dobijanje i terapeutska primena
DE3885115D1 (de) Verfahren zur Herstellung von Thiolen.
ATE90682T1 (de) Verfahren zur herstellung von cefodizim.
US5144043A (en) Cleavable bifunctional coupling agents
EP0147181A3 (de) Thiazolylessigsäure-Derivate und ihre Herstellung
YU7389A (en) Process for obtaining reagents for hydroxyalkylizing, this way obtained new reagents and their use
US5773271A (en) Compounds from biopolymers and effector substances which are linked via optically active amino acid derivatives, processes for the preparation thereof and the use thereof
SE7603640L (sv) Sett for framstellning av olosliga, biologiskt aktiva foreningar
JPS62246599A (ja) ビンブラスチン及びその誘導体の新規複合体、その製造法並びに製薬学的組成物
IL106692A (en) AZIDOALKYL DERIVATIVES AND THEIR USE FOR THE PREPARATION OF 99mTc COMPLEXES FOR IMAGING
ATE44746T1 (de) Verfahren zur herstellung eines 6-halogen-3methyl-1-trialkylsilyloxy-1,3,5-hexatrien.
KR870007898A (ko) 벤조[h]신놀린 화합물의 제조방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee